Phase 1/2 dose-ranging RCT of mRNA-1018 pandemic influenza vaccine candidates (H5 and H7) in healthy adults (1195 part A, 304 part B): solicited local reactions in 76.8%, systemic in 62.8%; immune responses tended to rise with dose.
RCT
Cosgrove et al. A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy Adults